Market Overview

The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Share:
The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY).

Here are the key catalysts that can sway biotech stocks in the unfolding week.

Invest in IPO shares before the stock hits the market with ClickIPO. Check it out here

Conferences

  • SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts
  • Canaccord Genuity Growth Conference - Aug. 7-8, in Boston

Clinical Trial Readouts

Leap Therapeutics Inc (NASDAQ: LPTX) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK)'s Keytruda in ornithine transcarbamylase deficiency.

Pending Mid-2019 Clinical Readouts

Immunic Inc (NASDAQ: IMUX) – interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis

Conatus Pharmaceuticals Inc (NASDAQ: CNAT) – 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis

Alkermes Plc (NASDAQ: ALKS) – Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis

IMMUTEP LTD/S ADR (NASDAQ: IMMP) – initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer

Aevi Genomic Medicine Inc (NASDAQ: GNMX) – Phase 1b data for AEVI-002 in pediatric onset Crohn's disease

Tricida Inc (NASDAQ: TCDA) – 12-month registration stability data from a Phase 3 study of TRC 101 in chronic kidney disease

Curis, Inc. (NASDAQ: CRIS) – Phase 1 data for CA-4948 in relapsed or refractory non-Hodgkin lymphoma

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) – Phase 1/2 data from the second cohort that is evaluating its DTX401 in Glycogen storage disease type 1 & Phase 1/2 third cohort data for DTX301 in ornithine transcarbamylase

Allakos Inc (NASDAQ: ALLK) – Phase 2 top-line data for AK002 in eosinophilic gastritis

Leap Therapeutics Inc (NASDAQ: LPTX)– Phase 1/2 data for DKN-01 + Keytruda in esophagogastric adenocarcinoma

Cidara Therapeutics Inc (NASDAQ: CDTX) – Phase 2 data for rezafungin in candidemia

Akcea Therapeutics Inc (NASDAQ: AKCA) - Phase 3 data for volanesorsen in familial partial lipodystrophy

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) and Zai Lab Ltd (NASDAQ: ZLAB) – Phase 3 data for DCC-2618 from a study dubbed INVICTUS in gastrointestinal stromal tumors

ZEALAND PHARMA/S ADR (NASDAQ: ZEAL) – Phase 1b data for dasiglucagon in obesity/diabetes

Aclaris Therapeutics Inc (NASDAQ: ACRS) – Phase 2 open label 6-month data for ATI-502 in vitiligo and Phase 2 data for ATI-502 in atopic dermatitis

AnaptysBio Inc (NASDAQ: ANAB) – Phase 2 data for ANB019 in generalized pustular psoriasis

Spark Therapeutics Inc (NASDAQ: ONCE) – additional Phase 1/2 data for SPK-8011 in hemophilia A

Earnings

Monday, Aug. 5

  • Acceleron Pharma Inc (NASDAQ: XLRN) (after the close)
  • Insulet Corporation (NASDAQ: PODD) (after the close)
  • Shockwave Medical Inc (NASDAQ: SWAV) (after the close)
  • Galmed Pharmaceuticals Ltd (NASDAQ: GLMD)

Tuesday, Aug. 6

  • Gamida Cell Ltd (NASDAQ: GMDA) (before the market open)
  • Karyopharm Therapeutics Inc (NASDAQ: KPTI) (before the market open)
  • GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) (after the close)
  • HTG Molecular Diagnostics Inc (NASDAQ: HTGM) (after the close)
  • Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) (after the close)

Wednesday, Aug. 7

  • Jounce Therapeutics Inc (NASDAQ: JNCE) (before the market open)
  • PDL BioPharma Inc (NASDAQ: PDLI) (after the close)
  • Cara Therapeutics Inc (NASDAQ: CARA) (after the close)
  • Sarepta Therapeutics Inc (NASDAQ: SRPT) (after the close)
  • Dynavax Technologies Corporation (NASDAQ: DVAX) (after the close)

Thursday, Aug. 8

  • Axsome Therapeutics Inc (NASDAQ: AXSM) (before the market open)
  • Achieve Life Sciences Inc (NASDAQ: ACHV) (before the market open)
  • Adamas Pharmaceuticals Inc (NASDAQ: ADMS) (after the close)
  • Nektar Therapeutics (NASDAQ: NKTR) (after the close)
  • Puma Biotechnology Inc (NASDAQ: PBYI) (after the close)

Friday, Aug. 9

  • Avadel Pharmaceuticals PLC (NASDAQ: AVDL) (before the market open)
  • Diplomat Pharmacy Inc (NYSE: DPLO) (before the market open)
  • PLx Pharma Inc (NASDAQ: PLXP) (before the market open)

IPO

BioVie, a biopharma company developing drug therapies for liver diseases, proposes to offer $1.26 million in an IPO, likely to be priced at $11.88. The company intends to list its shares on the Nasdaq under the ticker symbol BIVI.

Israeli medical device maker InMode filed for offering 5 million shares in an IPO, at an estimated price range of $14-$16. The shares are to be listed on the Nasdaq under the ticker symbol INMD.

Posted-In: Biotech Earnings News Previews IPOs Top Stories Trading Ideas Best of Benzinga

 

Related Articles (ACRS + ACHV)

View Comments and Join the Discussion!

Bulls And Bears Of The Week: Boeing, GM, Pfizer, Starbucks And More

Highlights From LeafLink's Q2 Cannabis Wholesale Report, Hits $1B In Orders